Journal international de l'inflammation, du cancer et de la thérapie intégrative

Abstrait

Sulforaphane Inhibits Liver Cancer Cell Growth and Angiogenesis

Dr. Moriya K1

Sulforaphane (SFN) exhibits inhibitory effects in different types of cancers. However,
its inhibitory effect on liver cancer remains unknown. This study aimed to determine
the therapeutic potential of SFN for the treatment of liver cancer and explore the
functional mechanisms underlying the inhibitory effects of SFN. Water-Soluble
Tetrazolium salt (WST-1) assay was performed to assess the in vitro effect of SFN on
cell proliferation in the human liver cancer cell lines, HepG2 and Huh-7. The mRNA
levels of Nrf2 target genes and cell cycle-related genes were determined using
quantitative RT-PCR. For assessing the inhibitory effect of SFN in vivo, we injected
immortalized liver cancer cells into BALB/c nude mice as a xenograft model. SFN
was orally administrated daily after tumor inoculation and continued for thirty-five
days until their sacrifices. Nrf2 activation, induced by SFN, was confirmed by mRNA
upregulation of HO-1, MRP2, and NQO1 in both the cell lines. Significant inhibition
of liver cancer cell proliferation by SFN was shown in vitro in a dose-dependent
manner by the downregulation of CCND1, CCNB1, CDK1 and CDK2. In in vivo
studies, the administration of SFN significantly reduced the subcutaneous tumor
burdens at the end of experiments by suppressing tumor cell proliferation, confirmed
by Ki67 immunohistochemically analysis. The mRNA levels of CCND1, CCNB1,
CDK1 and CDK2 were also decreased in these SFN- treated xenograft tumors.
Moreover, CD34 immunostaining elucidated that the intratumoral neovascularization
was markedly attenuated in the SFN-treated xenograft tumors. SFN exerts inhibitory
effect on human liver cancer cells with antiangiogenic activity. The earlier version of
this study was presented at the meeting of AASLD Liver Learning on Oct 2017